Retina

The lead gene therapy candidate, AXV-101, is expected to enter clinical development in mid-2025

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.

The program will deliver a range of high-quality access and affordability services for retina specialists.

The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the genetic defects in the BBS1 gene.

The scientific outputs from MACUSTAR’s study could impact more than 200 million patients with AMD globally

The AI-READI project aims to establish fair, equitable, and ethical access to big data, enhancing artificial intelligence’s ability to diagnose systemic diseases and drive progress in ophthalmology research.

The company states LYNX is the world’s first and only pattern scanning laser indirect ophthalmoscope and is battery-powered to provide surgeons with an untethered laser solution.

The investigators found that the premature births to be associated with vascular changes on ocular coherence tomography-angiography.

Diana V. Do, MD, spoke on behalf of the HELIOS investigators at the Hawaiian Eye and Retina 2025 Meeting, in Kauai, HI

The NeurEYE research team will use millions of eye scans from Scottish optometrists to create the data set.

Ultrasounds reveal the distinct feature within the vitreous anterior, a promising diagnostic indicator for ocular pathologies

The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.

ARCATUS or ARVN001 was developed by Clearside Biomedical and commercialised in the Asia-Pacific region by Arctic Vision

The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with retinitis pigmentosa.

Predictive software will use retinal imaging to identify patient risk for Alzheimer and other neurodegenerative diseases

Changes can result in bacterial contamination, loss of drug activity, and inflammation

The study findings suggest that patients should be educated about adherence to cold storage guidelines

The updated device is designed to meet market diagnostic needs, including within geographic atrophy research

Cost among other factors may deter patients from screening, especially in rural and low-resource settings.

The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy

Previously, Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).

The commercialisation agreements for the biosimilar to aflibercept (Eylea) cover Israel, major parts of Europe and the Asia-Pacific Region

The study built on previous research indicating specific retinal variables can serve as disease-related biomarkers in neurodegenerative diseases